Barinthus Biotherapeutics plc
BRNS
$0.839
$0.0161.94%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -18.78% | 42.34% | 28.87% | 14.80% | 18.39% |
| Total Depreciation and Amortization | -1.10% | 0.15% | 33.67% | 49.64% | 68.44% |
| Total Amortization of Deferred Charges | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Non-Cash Items | 138.84% | 154.50% | -59.99% | -82.79% | -36.50% |
| Change in Net Operating Assets | 239.24% | -285.20% | 168.63% | -84.43% | -323.42% |
| Cash from Operations | 166.76% | -62.61% | 29.20% | -272.46% | -72.82% |
| Capital Expenditure | -281.70% | -216.67% | 93.65% | 87.71% | 126.11% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -281.70% | -216.67% | 93.65% | 87.71% | 126.11% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 667.89% | 910.87% | 293.41% | -71.88% | -77.48% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 667.89% | 910.87% | 1,178.57% | -70.22% | -77.48% |
| Foreign Exchange rate Adjustments | -754.81% | 500.97% | -121.58% | -152.62% | -80.41% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 134.57% | 8.25% | 33.34% | -296.43% | -218.57% |